The papers that do not make headlines

Most research you hear about is research that found something. A compound protected cells. A treatment improved scores. A peptide reduced damage.

Studies that test a popular idea and find it does not hold up as expected rarely get the same attention. They are harder to publish, less exciting to share, and nobody puts them on a product page.

That is a shame, because they are often the most useful papers in a field. They tell you where the limits are.

This series is about one of those studies.

The claim being tested

SS-31, also called elamipretide, is a short peptide that targets mitochondria, the energy-producing structures inside cells. A string of animal studies has reported that it protects cells in conditions ranging from heart and kidney damage to eye disease and neurodegeneration.

One explanation offered for that protection is that SS-31 stops cells from killing themselves too early. More specifically, some studies, including the brain bleed study we cover in another series, reported that SS-31 stopped a protein called BAX from gathering on mitochondria. BAX is one of the key triggers of a cell's self-destruct sequence.

If that is how SS-31 works, it is a big deal. It would mean the peptide can step in at one of the central decision points of cell death.

A team at the University of Wisconsin-Madison decided to test that claim directly.

Who did the work

The study was led by Robert Nickells in the Department of Ophthalmology and Visual Sciences at the University of Wisconsin-Madison, with Joshua Grosser and Rachel Fehrman. Two co-authors, Dennis Keefe and Martin Redmon, worked for Stealth BioTherapeutics, the company developing elamipretide. The company also helped fund the study and supplied the peptide.

That last point matters, and I will come back to it properly in the final part. For now, note this: a study partly funded by the company behind the drug ended up publishing results that do not support one of the popular explanations for how that drug works.

What they found, in one paragraph

The team watched living cells go through the self-destruct process under a microscope, with BAX, a key signal protein and the mitochondria each tagged with a different colour. They gave some cells SS-31 and some cells nothing, then triggered cell death.

SS-31 made mitochondria grow larger, faster. It also slowed BAX down slightly as it gathered on the mitochondria. But it did not delay when BAX started gathering, did not reduce how much BAX gathered in the end, and did not stop the signals that follow.

Their conclusion: whatever SS-31 does to protect cells, it is not by blocking BAX once the death process has started.

Why that is a useful result

At first glance, that sounds like bad news for SS-31. It is more interesting than that.

It does not say SS-31 is useless. It says one specific explanation for how it works does not hold up in this experimental setup. That narrows the search. If SS-31 protects cells, and many studies suggest it does in animals, the protection probably happens somewhere else, perhaps before the death process starts, perhaps by keeping mitochondria healthier so the death signal is never sent.

That is how science is supposed to work. You propose a mechanism, someone tests it carefully, and either it holds up or you learn to look elsewhere.

What this series will cover

Over the next seven parts we will look at:

  • What BAX is and how it pulls the trigger on cell death
  • Cardiolipin, the unusual fat that SS-31 binds to, and why the researchers thought it might matter
  • How you watch a single cell die in real time, every two minutes
  • The finding that SS-31 helps mitochondria grow larger
  • The small slowdown in BAX and why it did not change the outcome
  • What the results say about how SS-31 does not work
  • And finally, the funding question and the real limits of this kind of experiment

If you have read our brain bleed series, this one will give you a second angle on the same peptide. If you have not, it stands on its own.

The whole series is about a laboratory study in cells grown in dishes. It is a precise test of a mechanism. It is not evidence about what SS-31 does in a living animal or a person.

This series discusses a peer-reviewed laboratory study in cultured cells. The results have not been shown in people. Nothing here is medical advice, and SS-31 is discussed for research purposes only.